Management of Pediatric Community-Acquired Pneumonia in the Era of Widespread Vaccination against Streptococcus Pneumoniae at a First-Level Hospital
DOI:
https://doi.org/10.12974/2311-8687.2023.11.02Keywords:
CAP, Children, Hospitalization, Infection, North-Italy, Pneumococcal, Respiratory, VaccineAbstract
Community-acquired pneumonia (CAP) is a common and potentially severe infection affecting children. A retrospective study was carried out at our Institution between November 2022 and January 2023. Twenty-eight patients under 14 years of age were diagnosed and treated accordingly. Median age was 35 months, half of the patients were males. The most detected pathogen was S. pneumoniae (in 36% of all patients). Other pathogens detected were RSV in 3 patients (11%), influenza B virus in two patients (7%), adenovirus in two patients (7%), and M. pneumoniae in one patient (4%). Fourteen children (50% of the total number) developed a respiratory failure that required supplemental oxygen. Among these, 8 children (57% of all children receiving oxygen supplementation) required low-flow oxygen delivery, four children (29%) required high-flow oxygen delivery, and one child (7%) required invasive ventilation. Five children (55% of children with a bacterial CAP) received intravenous antibiotics, while 44% of patients received oral antibiotics. First-line intravenous antibiotics consisted of a third-generation cephalosporin for infants and children older than 1 month, and ampicillin/sulbactam with gentamicin for newborns. Amoxy-clavulanic acid was the first-line oral antibiotic for pneumococcal CAP, while oral clarithromycin was the first line antimicrobic for CAP caused by M. pneumoniae.
Twenty-one children (75% of total patients) were fully vaccinated, three children (11%) had received two doses because of age. Regarding the 10 children with a pneumococcal CAP, seven (70%) were fully vaccinated, one had received two-doses of pneumococcal conjugate vaccine (PCV), and two were unvaccinated.
References
O'Reilly R, Lu H, Kwong JC, McGeer A, To T, Sander B. Tepidemiology and healthcare costs of community-acquirpneumonia in Ontario, Canada: a population-based coh study. J Med Econ 2023 Jan-Dec; 26(1): 293-302. https://doi.org/10.1080/13696998.2023.2176679 DOI: https://doi.org/10.1080/13696998.2023.2176679
Lokida D, Farida H, Triasih R, Mardian Y, Kosasih H, Naysilla AM, et al. Epidemiology of community-acquired pneumonia among hospitalised children in Indonesia: a multicentre, prospective study. BMJ Open 2022; 12(6): e057957. https://doi.org/10.1136/bmjopen-2021-057957 DOI: https://doi.org/10.1136/bmjopen-2021-057957
Dupuis C, Sabra A, Patrier J, Chaize G, Saighi A,Féger C, et al. Burden of pneumococcal pneumonia requiring ICU admission in France: 1-year prognosis, resources use, and costs. Crit Care 2021; 25(1): 24. https://doi.org/10.1186/s13054-020-03442-z DOI: https://doi.org/10.1186/s13054-020-03442-z
Cardinale F, Cappiello AR, Mastrototaro MF, Pignatelli M, Esposito S. Community-acquired pneumonia in children. Early Hum Dev 2013; 89(Suppl 3): S49-52. https://doi.org/10.1016/j.earlhumdev.2013.07.023 DOI: https://doi.org/10.1016/j.earlhumdev.2013.07.023
Ferreira-Coimbra J, Sarda C, Rello J. Burden of communityacquired pneumonia and unmet clinical needs. Adv Ther 2020; 37: 1302-18. https://doi.org/10.1007/s12325-020-01248-7 DOI: https://doi.org/10.1007/s12325-020-01248-7
Nasreen S, Wang J, Sadarangani M, Kwong JC, Quach C, Crowcroft NS, et al. Estimating population-based incidence of community-acquired pneumonia and acute otitis media in children and adults in Ontario and British Columbia using health administrative data, 2005-2018: a Canadian Immunisation Research Network (CIRN) study. BMJ Open Respir Res 2022; 9(1): e001218. https://doi.org/10.1136/bmjresp-2022-001218 DOI: https://doi.org/10.1136/bmjresp-2022-001218
Feng Z, Xu B, Zhong L, Chen J, Deng J, Luo Z, et al. A multicentre study on the incidence of respiratory viruses in children with community-acquired pneumonia requiring hospitalization in the setting of the zero-COVID policy in China. Arch Virol 2023; 168(2): 64. https://doi.org/10.1007/s00705-023-05698-6 DOI: https://doi.org/10.1007/s00705-023-05698-6
Roh EJ, Lee M, Lee YJ, Kim H, Ahn YM, Kim JK, et al. Analysis of national surveillance of respiratory pathogens for community-acquired pneumonia in children and adolescents. BMC Infect Dis 2022; 22(1): 330. https://doi.org/10.1186/s12879-022-07263-z DOI: https://doi.org/10.1186/s12879-022-07263-z
Oumei H, Xuefeng W, Jianping L, Kunling S, Rong M, Zhenze C, et al. Etiology of community-acquired pneumonia in 1500 hospitalized children. J Med Virol 2018; 90(3): 421- 428. https://doi.org/10.1002/jmv.24963 DOI: https://doi.org/10.1002/jmv.24963
Dabaja-Younis H, Geller D, Geffen Y, Almog R, Kassis I. The impact of pneumococcal conjugate vaccine-13 on the incidence of pediatric community-acquired bacteremia. European Journal of Clinical Microbiology & Infectious Diseases 2021; 40: 1433-1439. https://doi.org/10.1007/s10096-021-04167-9 DOI: https://doi.org/10.1007/s10096-021-04167-9
Greenberg D, Givon-Lavi N, Ben-Shimol S, Bar Ziv J, Dagan R. Impact of PCV7/PCV13 introduction on community- acquired alveolar pneumonia in children <5 years. Vaccine 2015; 33(36): 4623-9. https://doi.org/10.1016/j.vaccine.2015.06.062 DOI: https://doi.org/10.1016/j.vaccine.2015.06.062
Alicino C, Paganino C, Orsi A, Astengo M, Trucchi C, Icardi G, et al. The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on hospitalization for pneumonia in children: A systematic review and metaanalysis. Vaccine 2017; 35: 5776-5785. https://doi.org/10.1016/j.vaccine.2017.09.005
Eichler N, Joseph L, Megged O, Goldberg S, Picard E. The impact of pneumococcal conjugate vaccine on the prevalence and severity of hospitalizations for pneumonia in children. Eur J Clin Microbiol Infect Dis 2022; 41(3): 439-444. https://doi.org/10.1007/s10096-021-04386-0 DOI: https://doi.org/10.1007/s10096-021-04386-0
Ministero della salute. Piano Nazionale Prevenzione Vaccinale 2012-2014. Gazzetta Ufficiale n.60 del 12.3.12. http: //www.sanita.ilsole24ore.com/Sanita/Archivio/Normativa%20 e%20varie/PIANO%20VACCINI%202012_2014%20IN20GU. pdfcmd=art&codid=27.1.240156858.
Monali R, De Vita E, Mariottini F, Privitera G, Lopalco PL, Tavoschi L. Impact of vaccination on invasive pneumococcal disease in Italy 2007-2017: surveillance challenges and epidemiological changes. Epidemiol Infect 2020; 148: e187. https://doi.org/10.1017/S0950268820001077 DOI: https://doi.org/10.1017/S0950268820001077
Ministero della salute. Vaccinazioni dell'età pediatrica e dell'adolescenza - coperture vaccinali. https: //www.salute.gov.it/portale/documentazione/p6_2_8_3_1.jsp ?id=20.
Ricketson LJ, Bettinger JA, Sadarangani M, Halperin SA, Kellner JD. Vaccine effectiveness of the 7-valent and 13- valent pneumococcal conjugate vaccines in Canada: An IMPACT study. Vaccine 2022; 40(19): 2733-2740. https://doi.org/10.1016/j.vaccine.2022.03.048 DOI: https://doi.org/10.1016/j.vaccine.2022.03.048
Ouldali N, Levy C, Minodier P, Morin L, Biscardi S, Aurel M, et al. Long-term Association of 13-Valent Pneumococcal Conjugate Vaccine Implementation With Rates of Community-Acquired Pneumonia in Children. JAMA Pediatr 2019; 173(4): 362-370. https://doi.org/10.1001/jamapediatrics.2018.5273 DOI: https://doi.org/10.1001/jamapediatrics.2018.5273
Alicino C, Paganino C, Orsi A, et al. The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on hospitalization for pneumonia in children: a systematic review and meta-analysis. Vaccine. 2017; 35(43): 5776-5785. https://doi.org/10.1016/j.vaccine.2017.09.005 DOI: https://doi.org/10.1016/j.vaccine.2017.09.005
Wu DB, Chaiyakunapruk N, Chong HY, Beutels P. Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: a review of economic evaluations (2006-2014). Vaccine 2015; 33(14): 1633-58. https://doi.org/10.1016/j.vaccine.2015.01.081 DOI: https://doi.org/10.1016/j.vaccine.2015.01.081
Savulescu C, Krizova P, Valentiner-Branth P, Ladhani S, Rinta-Kokko H, Levy C, et al. Effectiveness of 10 and 13valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study. Vaccine 2022; 40(29): 39633974. https://doi.org/10.1016/j.vaccine.2022.05.011 DOI: https://doi.org/10.1016/j.vaccine.2022.05.011
Gutiérrez-Tobar IF, Londoño-Ruiz JP, Mariño-Drews C, Beltrán-Higuera S, Camacho-Moreno G, Leal-Castro AL, et al. Epidemiological characteristics and serotype distribution of culture-confirmed pediatric pneumococcal pneumonia before and after PCV 10 introduction, a multicenter study in Bogota, Colombia, 2008-2019. Vaccine 2022; 40(20): 28752883. https://doi.org/10.1016/j.vaccine.2022.03.022 DOI: https://doi.org/10.1016/j.vaccine.2022.03.022